Patents by Inventor Kenneth O. Lloyd
Kenneth O. Lloyd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7550146Abstract: The present invention provides novel glycoconjugates such as glycopeptides, as well as convergent methods for the synthesis thereof. An exemplary preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the glycoconjugates of the invention.Type: GrantFiled: July 23, 2004Date of Patent: June 23, 2009Assignee: Sloan-Kettering Institute For Cancer ResearchInventors: Samuel J. Danishefsky, Dalibor Sames, Samuel Hintermann, Peter Glunz, Govindaswami Ragupathi, Philip O. Livingston, Kenneth O. Lloyd, Valery Kudryashov
-
Patent number: 7205142Abstract: The present invention provides an isolated nucleic acid molecule comprising sequences encoding the CA125 protein or a portion thereof. This invention also provides a method to detect ovarian cancer in a subject. Furthermore, this invention provides a method for the diagnosis of a cancer which expresses CA125 by detecting CA125-expressing cells in the blood or other fluids of patients. This invention also provides a method of producing CA125 protein. This invention also provides a method of silencing CA125 protein production. Finally, this invention provides a method to treat or prevent cancer using a vaccine comprising CA125 nucleic acid or protein.Type: GrantFiled: September 13, 2002Date of Patent: April 17, 2007Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Kenneth O. Lloyd, Beatrice W. T. Yin
-
Publication number: 20040102607Abstract: The present invention provides novel &agr;-O-linked glycoconjugates such as &agr;-O-linked glycopeptides, as well as convergent methods for the synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the &agr;-O-linked glycoconjugates.Type: ApplicationFiled: June 19, 2003Publication date: May 27, 2004Inventors: Samuel J. Danishefsky, Dalibor Sames, Samuel Hintermann, Xiao Tao Chen, Jacob B. Schwarz, Peter Glunz, Govindaswami Ragupathi, Philip O. Livingston, Scott Kuduk, Kenneth O. Lloyd, Lawrence Williams, Valery Kudryashov
-
Patent number: 6645935Abstract: The present invention provides a method of synthesizing an allyl pentasaccharide having the structure: as well as related oligosaccharide ceramides and other glycoconjugates useful as vaccines for inducing antibodies to epithelial cancer cells in an adjuvant therapy therefor, and in a method for preventing recurrence of epithelial cancer.Type: GrantFiled: October 12, 2001Date of Patent: November 11, 2003Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City New YorkInventors: Samuel J. Danishefsky, Victor Behar, Kenneth O. Lloyd
-
Publication number: 20030104442Abstract: The present invention provides an isolated nucleic acid molecule comprising sequences encoding the CA125 protein or a portion thereof. This invention also provides a method to detect ovarian cancer in a subject. Furthermore, this invention provides a method for the diagnosis of a cancer which expresses CA125 by detecting CA125-expressing cells in the blood or other fluids of patients. This invention also provides a method of producing CA125 protein. This invention also provides a method of silencing CA125 protein production. Finally, this invention provides a method to treat or prevent cancer using a vaccine comprising CA125 nucleic acid or protein.Type: ApplicationFiled: September 13, 2002Publication date: June 5, 2003Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: Kenneth O. Lloyd, Beatrice W.T. Yin
-
Publication number: 20030078399Abstract: The present invention provides an isolated nucleic acid molecule comprising sequences encoding the CA125 protein or a portion thereof. This invention also provides a method to detect ovarian cancer in a subject. Furthermore, this invention provides a method for the diagnosis of a cancer which expresses CA125 by detecting CA125-expressing cells in the blood or other fluids of patients. This invention also provides a method of producing CA125 protein. Finally, this invention provides a method to treat or prevent cancer using a vaccine comprising CA125 nucleic acid or protein.Type: ApplicationFiled: May 9, 2002Publication date: April 24, 2003Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: Kenneth O. Lloyd, Beatrice W.T. Yin
-
Publication number: 20020038017Abstract: The present invention provides a method of synthesizing an allyl pentasaccharide having the structure: 1Type: ApplicationFiled: October 12, 2001Publication date: March 28, 2002Applicant: The Trustees of Columbia UniversityInventors: Samuel J. Danishefsky, Victor Behar, Kenneth O. Lloyd
-
Publication number: 20020006629Abstract: An affinity matrix having a tumor-associated carbohydrate- or glycopeptide-based antigen bound to the matrix is provided. The affinity matrix is used to isolate, characterize, and quantitate functional antibodies or antigen-binding molecules to the tumor-associated carbohydrate- or glycopeptide-based antigen. The invention also provides a method of preparing the affinity matrix. In addition the invention provides for diagnostic and therapeutic uses of the isolated antibodies or antigen-binding molecules.Type: ApplicationFiled: February 27, 2001Publication date: January 17, 2002Inventors: Samuel J. Danishefsky, Kenneth O. Lloyd, Zhi-Guang Wang, Lawrence J. Williams
-
Patent number: 6303120Abstract: The present invention provides a method of synthesizing an allyl pentasaccharide having the structure: as well as related oligosaccharide ceramides and other glycoconjugates useful as vaccines for inducing antibodies to epithelial cancer cells in an adjuvant therapy therefor, and in a method for preventing recurrence of epithelial cancer.Type: GrantFiled: July 24, 1995Date of Patent: October 16, 2001Assignee: Memorial Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Victor Behar, Kenneth O. Lloyd
-
Patent number: 5173292Abstract: This invention provides a composition useful for diagnosing cancer which specifically recognizes a galactosyl-globoside. Preferably, the composition is a monoclonal antibody which specifically recognize the galactosyl-globoside antigen, gal-Gb4.Additionally, the present invention provides two hybridoma cell lines, designated J309 and D579, which produce monoclonal antibodies that specifically recognize gal-Gb4.The invention also provides a method of diagnosing a carcinoma which comprises contacting a sample from a human subject with a composition which specifically recognizes a galactosyl-globoside antigen and is labeled with a detectable moiety, under suitable conditions so as to form a detectable complex. The amount of formed complex is then quantified and correlated with values obtained from subjects devoid of carcinomas.Type: GrantFiled: June 14, 1988Date of Patent: December 22, 1992Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David S. Schrump, Koichi Furukawa, Hiroshi Yamaguchi, Kenneth O. Lloyd, Lloyd J. Old
-
Patent number: 5168043Abstract: The subject invention describes a method of determining the secretor status of an individual which comprises obtaining a sample of a biological fluid from the individual and determining whether the sample includes the Lewis.sup.a or Lewis.sup.b antigens, the presence of the Lewis.sup.a antigen in the sample indicating that the individual is a nonsecretor, the presence of the Lewis.sup.b antigen in the sample indicating that the individual is a secretor, and the presence of neither antigen indicating the secretor status of the individual is inconclusive. The invention also provides a method of further determining the secretor status of an individual of having an inconclusive secretor status which comprises determining whether the biological fluid sample from the individual includes A, B or precursor type 1 chain antigens, the presence of any such antigens in the sample indicating that the individual is a secretor, the lack of any such antigens in the sample indicating that the individual is a nonsecretor.Type: GrantFiled: March 28, 1989Date of Patent: December 1, 1992Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Carlos Cordon-Cardo, Kenneth O. Lloyd, Connie L. Finstad, Lloyd J. Old, Mryon R. Melamed, Joel Sheinfeld
-
Patent number: 5143843Abstract: Monoclonal antibodies to human antigens present on a majority of human cells are described. These mAbs have use in a method for isolating mAb for less expressive antigens, such as cancer antigens, or other antigens associated with particular abnormalities, disorders or disease state. The latter mAbs may be weaker than or not present to such an extent as the first mentioned mAbs. For example, these less expressive mAbs would be useful for cancer diagnosis, especially in the early stages, and for cancer treatment as well where the cancer cell is the target cell for the mAb. The mAb can be tagged with a tissue destructive agent such as a radio-label, a toxin, a chemical poisen, and the like. Some of the mAbs described, subset tumors of particular types and so are useful for tumor subclassification. The mAbs described are also useful in analyzing the properties and functions of their respective antigens in human cells.Type: GrantFiled: July 18, 1991Date of Patent: September 1, 1992Assignee: Sloan-Kettering Institute For Cancer ResearchInventors: M. Jules Mattes, Lloyd J. Old, Kenneth O. Lloyd
-
Patent number: 5006470Abstract: This invention provides a monoclonal antibody, produced by the hybridoma cell line designated GXM1, which specifically binds to a human class 1tumor antigen. This invention also provides a human monoclonal antibody, produced by a hybridoma cell line designated HJM1, which specifically binds to each of the ganglioside antigens GD2, GD3, GM3 and GD1b. This invention further provides a human monoclonal antibody, produced by a hybridoma cell line designated FCM1, which specifically binds to the ganglioside antigens GM3 and GD1a. Finally, this invention provides a human monoclonal antibody, produced by a hybridoma cell line designated DSM1, which specifically binds to a human class 2 tumor protein antigen.Type: GrantFiled: April 16, 1987Date of Patent: April 9, 1991Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Hiroshi Yamaguchi, Koichi Furukawa, Philip O. Livingston, Kenneth O. Lloyd, Herbert F. Oettgen, Lloyd J. Old, Sheila R. Fortunato
-
Patent number: 4892828Abstract: This invention concerns a new monoclonal antibody (mAb) 4C, recognizing a specific antigen, Leu 200, found in human hematopoietic tissues. The monoclonal antibody precipitates a series of glycoproteins (Leu 200) with a molecular weight range of about 190,000 to 230,000 from both T- and B-cell lines. The series of glycoproteins resolves into four discrete glycoprotein bands, the distribution of which varies according to the cell lines. Bands 3 and 4 predominate in a majority of T-cells whereas band 2 predominates in B cells. Thus, a Leu 200 antigen subset distribution is possible with mAb 4C. Bands 1, 2, 3, 4 have apparent molecular weights of 230K, 215K, 205K, and 190K respectively, with differences in their carbohydrate moieties. nAb 4C is a IgG sub two a,kappa immunoglobulin. 4C has potential use in leukemia, hematopoietic cell differentiation and transplantation diagnoses and therapy.Type: GrantFiled: November 16, 1987Date of Patent: January 9, 1990Assignee: Sloan-Kettering Institute For Cancer ResearchInventors: Bo Dupont, Yasuo Morishima, Nancy Collins, Shun-ichiro Ogata, Kenneth O. Lloyd
-
Patent number: 4865998Abstract: A panel of monoclonal antibodies produced from normal human lung fibroblasts and human lung tumors as immunogen is used to diagnose the presence of lung tumors and differentiate between those which are benign and those which are cancerous.Type: GrantFiled: August 10, 1987Date of Patent: September 12, 1989Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Hans-Joachim Feickert, Wolfgang Rettig, Karen Chorney, Carlos Cordon-Cardo, Myron R. Melamed, Kenneth O. Lloyd, Herbert F. Oettgen, Lloyd J. Old, Bernd Anger
-
Patent number: 4808704Abstract: Monoclonal antibody recognizing human melanoma cells, method of production and use.Type: GrantFiled: May 22, 1986Date of Patent: February 28, 1989Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Lloyd J. Old, Herbert F. Oettgen, Hisami Ikeda, Lucy T. C. Li, Kenneth O. Lloyd, Wolfgang G. Dippold
-
Patent number: 4798790Abstract: Monoclonal antibody TA99, which specifically binds to a pigmentation associated antigen present on melanoma cells is described. Additionally, the hybridoma cell line deposited with the ATCC under Accession Number HB 8704 from which the antibody is derived, as well as methods for using the antibody are described.Type: GrantFiled: July 18, 1985Date of Patent: January 17, 1989Assignee: Sloan-Kettering InstituteInventors: Timothy M. Thomson, M. Jules Mattes, Lloyd J. Old, Kenneth O. Lloyd, Linda Roux
-
Patent number: 4762800Abstract: Antibody-producing hybridoma cell lines made by fusion of NS/1 cells with spleen cells of mice after immunization with human teratocarcinoma cells are presented. Monoclonal antibodies from these cell lines recognize the K4, K2 and P12 antigenic systems and are thus useful in detecting and differentiating between normal and cancerous cells. These monoclonal antibodies are especially useful in pathologic analysis of human tumors, especially teratocarcinomas.Type: GrantFiled: April 26, 1984Date of Patent: August 9, 1988Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Wolfgang Rettig, Carolos Cordon-Cardo, Herbert F. Oettgen, Lloyd J. Old, Kenneth O. Lloyd, Jennifer Ng
-
Patent number: 4710457Abstract: This invention concerns a new monoclonal antibody (mAb) 4C, recognizing a specific antigen, Leu 200, found in human hematopoietic tissues. The monoclonal antibody precipitates a series of glycoproteins (Leu 200) with a molecular weight range of about 190,000 to 230,000 from both T- and B-cell lines. The series of glycoproteins resolves into four discrete glycoprotein bands, the distribution of which varies according to the cell lines. Bands 3 and 4 predominate in a majority of T-cells whereas band 2 predominates in B cells. Thus, a Leu 200 antigen subset distribution is possible with mAb 4C. Bands 1, 2, 3, 4 have apparent molecular weights of 230K, 215K, 205K, and 190K respectively, with differences in their carbohydrate moieties. mAb 4C is a IgG sub two a, kappa immunoglobulin. 4C has potential use in leukemia, hematopoietic cell differentiation and transplantation diagnoses and therapy.Type: GrantFiled: June 29, 1983Date of Patent: December 1, 1987Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Bo Dupont, Yasuo Morishima, Nancy Collins, Shun-ichiro Ogata, Kenneth O. Lloyd
-
Patent number: 4678747Abstract: Monoclonal antibodies recognizing the difucosyl-type-2-H antigen on human cells and a method of producing said antibodies are disclosed. The monoclonal antibodies are useful in blood typing and in diagnosis of blood disorders and malignancies involving loss or gain of this H antigen.Type: GrantFiled: February 28, 1983Date of Patent: July 7, 1987Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Kenneth O. Lloyd, Lloyd J. Old, Karl-Anders Karlsson, Goran Larson, Nicklas Stromberg, Jan Thurin, Bernd R. Anger, Herbert F. Oettgen